Skip to main content
    I

    Invivyd Inc. (IVVD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    -0.04 (-7.63%)

    Market Cap: $171.58M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Invivyd Inc. (IVVD) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Invivyd are Compass Therapeutics (CMPX), Armata Pharmaceuticals (ARMP) and Atrium Therapeutics, Inc. Common Stock (RNA). By market cap, Invivyd ranks 4th of the 13 companies on this page; SAB Biotherapeutics (SABS) is the largest at $266.66M.

    Peer Comparison

    IVVD's revenue growth of 21.2% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Invivyd (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    Armata Pharmaceuticals Inc (ARMP)$143.94MN/A14.7x0.0%-184.6%173.6%0.00%
    Atrium Therapeutics, Inc. Common Stock (RNA)$162.00MN/A3.3x-180.9%-44.5%24.2%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Fate Therapeutics Inc (FATE)$155.74MN/A29.7x0.0%-51.3%9.2%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    SAB Biotherapeutics Inc (SABS)$266.66MN/AN/A0.0%N/A-62.4%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    MacroGenics Inc (MGNX)$140.60MN/A1.2x-36.6%-108.7%-64.8%0.00%
    Entrada Therapeutics Inc (TRDA)$199.28MN/A53.3x0.0%-69.7%-43.9%0.00%
    Molecular Partners AG ADR (MOLN)$112.71MN/AN/A0.0%N/A-100.0%0.00%
    Peer median$154.94MN/A16.2x0.0%-60.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Invivyd, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors
    Armata Pharmaceuticals Inc (ARMP)
    Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment...
    ARMP competitors
    Atrium Therapeutics, Inc. Common Stock (RNA)
    Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies.
    RNA competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Fate Therapeutics Inc (FATE)
    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally.
    FATE competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    SAB Biotherapeutics Inc (SABS)
    SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology.
    SABS competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors
    MacroGenics Inc (MGNX)
    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States.
    MGNX competitors
    Entrada Therapeutics Inc (TRDA)
    Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by...
    TRDA competitors
    Molecular Partners AG ADR (MOLN)
    Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland.
    MOLN competitors

    Frequently Asked Questions About IVVD

    Who are Invivyd's main competitors?

    The companies most similar to Invivyd include Compass Therapeutics (CMPX), Armata Pharmaceuticals (ARMP), Atrium Therapeutics, Inc. Common Stock (RNA), Innate Pharma (IPHA) and Arcturus Therapeutics Holdings (ARCT), listed from the closest match.

    Who is Invivyd's biggest competitor?

    SAB Biotherapeutics (SABS) is the largest of the similar companies at $266.66M; Compass Therapeutics (CMPX) is the closest match by business profile, size, sector and industry.

    How does IVVD stock compare with its competitors?

    IVVD's P/S is 2.9x against a peer median of 16.2x; its net margin is -183.9% against a peer median of 0.0%.

    Which of Invivyd's competitors pays a higher dividend?

    Invivyd pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Invivyd bigger than its competitors?

    No. Invivyd is 4th by market cap among the 13 companies on this page; the largest is SAB Biotherapeutics (SABS) at $266.66M.